WO2016116882A3 - Novel compositions of carfilzomib - Google Patents

Novel compositions of carfilzomib Download PDF

Info

Publication number
WO2016116882A3
WO2016116882A3 PCT/IB2016/050289 IB2016050289W WO2016116882A3 WO 2016116882 A3 WO2016116882 A3 WO 2016116882A3 IB 2016050289 W IB2016050289 W IB 2016050289W WO 2016116882 A3 WO2016116882 A3 WO 2016116882A3
Authority
WO
WIPO (PCT)
Prior art keywords
carfilzomib
novel compositions
relates
solvates
hydrates
Prior art date
Application number
PCT/IB2016/050289
Other languages
French (fr)
Other versions
WO2016116882A2 (en
Inventor
Kocherlakota Chandrashekhar
Banda Nagaraju
Original Assignee
Leiutis Pharmaceuticals Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leiutis Pharmaceuticals Pvt Ltd filed Critical Leiutis Pharmaceuticals Pvt Ltd
Publication of WO2016116882A2 publication Critical patent/WO2016116882A2/en
Publication of WO2016116882A3 publication Critical patent/WO2016116882A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

The invention relates to novel parenteral compositions of Carfilzomib or its pharmaceutically acceptable salts, solvates and hydrates thereof. More specifically, the invention relates to cyclodextrin free lyophilized formulations of Carfilzomib.
PCT/IB2016/050289 2015-01-23 2016-01-21 Novel compositions of carfilzomib WO2016116882A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN339/CHE/2015 2015-01-23
IN339CH2015 2015-01-23

Publications (2)

Publication Number Publication Date
WO2016116882A2 WO2016116882A2 (en) 2016-07-28
WO2016116882A3 true WO2016116882A3 (en) 2016-11-03

Family

ID=56417892

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2016/050289 WO2016116882A2 (en) 2015-01-23 2016-01-21 Novel compositions of carfilzomib

Country Status (1)

Country Link
WO (1) WO2016116882A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018138556A1 (en) * 2017-01-24 2018-08-02 Orbicular Pharmaceutical Technologies Pvt. Ltd. Non-aqueous carfilzomib compositions
CN107802606A (en) * 2017-12-11 2018-03-16 齐鲁制药(海南)有限公司 A kind of injection Carfilzomib and preparation method thereof
WO2020055360A2 (en) * 2018-08-10 2020-03-19 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi The parenteral composition comprising carfilzomib
WO2021142359A1 (en) * 2020-01-10 2021-07-15 Amgen Inc. Stable cyclodextrin free carfilzomib formulation
EP4087538A1 (en) * 2020-01-10 2022-11-16 Amgen, Inc. Stable cyclodextrin free carfilzomib formulation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8207125B2 (en) * 2004-04-15 2012-06-26 Onyx Therapeutics, Inc. Compounds for enzyme inhibition
US20140073583A1 (en) * 2012-09-11 2014-03-13 Innopharma, Inc. Stable compositions of peptide epoxy ketones
WO2015198257A1 (en) * 2014-06-26 2015-12-30 Intas Pharmaceuticals Ltd. Stable carfilzomib injection

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8207125B2 (en) * 2004-04-15 2012-06-26 Onyx Therapeutics, Inc. Compounds for enzyme inhibition
US20140073583A1 (en) * 2012-09-11 2014-03-13 Innopharma, Inc. Stable compositions of peptide epoxy ketones
WO2015198257A1 (en) * 2014-06-26 2015-12-30 Intas Pharmaceuticals Ltd. Stable carfilzomib injection

Also Published As

Publication number Publication date
WO2016116882A2 (en) 2016-07-28

Similar Documents

Publication Publication Date Title
EP3582790A4 (en) High potency immunogenic compositions
PL3668937T3 (en) Compositions and uses of z-1-chloro-2,3,3,3-tetrafluoroprop-1-ene
EP3642182A4 (en) Compounds, compositions and methods for synthesis
EP3615040A4 (en) Hair-treatment compositions
EP3665156A4 (en) Compounds, compositions and methods
WO2018025089A3 (en) Intranasal pharmaceutical powder compositions
EP3600325A4 (en) Novel compositions and methods
EP3676297A4 (en) Compounds, compositions and methods
EP4279071A3 (en) Novel cannabinoid formulations
EP3112364A4 (en) 2,4-disubstituted phenylene-1,5-diamine derivatives and applications thereof, and pharmaceutical compositions and pharmaceutically acceptable compositions prepared therefrom
EP3641771A4 (en) Pharmaceutical compositions
EP3474884A4 (en) Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties
WO2016044463A3 (en) Mk2 inhibitors and uses thereof
SG10201909805XA (en) Surface modified polymer compositions
WO2016116882A3 (en) Novel compositions of carfilzomib
EP3880194A4 (en) Deuterated compounds, compositions, and uses
EP3630150A4 (en) Purified anthelmintic compositions and related methods
WO2017011340A3 (en) Proteins and immunizing compositions containing klebsiella proteins and methods of use
WO2016020210A8 (en) Factor viii formulation
EP3675804A4 (en) Cosmetic compositions having antioxidant properties
SG11202004773SA (en) Immunostimulatory compositions
EP3870208A4 (en) Zika virus immunogenic compositions
EP3659580A4 (en) Cleanser composition
WO2015172040A3 (en) IMMUNOMODULATING β-1,6-D-GLUCANS
IL291559A (en) Immunogenic compositions

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16739862

Country of ref document: EP

Kind code of ref document: A2